NLS Pharma - NLSP Net earnings per share growth forecast for next year

Corporate company logo of NLS Pharmaceutics (NLSP)

The digitalization of clinical data analysis at NLS Pharmaceutics AG (NLSP) accelerates hypothesis testing, confirming the consensus on next year's earnings per share, where the 0.00 mark reflects the latest data. The development of treatments for ADHD and sleep disorders minimizes regulatory capital risks. Simultaneously, the company is modernizing its laboratory capacities by implementing automated control within clean booths.

NLS Pharma (NLSP): Net earnings per share growth forecast for next year from 07/04/2022 to 10/31/2025

Summary analytical data breakdowns for NLS Pharmaceutics AG (NLSP)

- price and consensus price forecast:
Price Chart nlspharma.com|NLSP - Fair Value Consensus
- issuer market value details:
Market Value NLS Pharmaceutics|NLSP - Total Enterprise Value
- company book value details:
Net Assets per Single Share NLS Pharmaceutics|NLSP - Company Book Value|Market Value to Book Value Ratio nlspharma.com|NLSP - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital NLS Pharmaceutics AG|NLSP - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio NLS Pharmaceutics Ltd.|NLSP - Company Cumulative Debt|Debt to Book Capitalization Ratio NLS Pharmaceutics|NLSP - Company Long-Term Indebtedness|Company Short-Term Debt NLS Pharmaceutics|Quick Liquidity nlspharma.com
- net income and valuation ratios data:
NLSP - Net Financial Result|Future Profit NLS Pharmaceutics AG|NLSP - Company Value to Net Income|Future Price to Earnings NLS Pharma|NLSP - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple NLS Pharma|NLSP - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) NLS Pharmaceutics|NLSP - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months nlspharma.com|NLSP - Earnings per share increase in current year|Net earnings per share growth forecast for next year NLS Pharmaceutics AG
- company sales and revenue statistics:
NLSP - Company Sales|Projected Sales Volume NLS Pharma|NLSP - P/S Multiple|Forward P/S Multiple NLS Pharma
Fundamental company analysis:NLSP, NLS Pharma
Finished products of NLS Pharma

This indicator measures the consensus forecast for earnings changes over the coming year, reflecting the speed at which the market re-evaluates business value through expected EPS dynamics. By analyzing the valuation of forward net income growth rates, an investor can gauge the asset's sensitivity to the clinical successes of NLS Pharmaceutics AG (NLSP), where the binary risk of sleep disorder drug development determines the company's entire future profitability.

Competing companies

Net earnings per share growth forecast for next year Jazz Pharmaceuticals|CYTK: Expected earnings per share trend next year|Net earnings per share growth forecast for next year PTC Bio (PTCT)|SRRK - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Centessa Pharmaceuticals PLC CNTA|Dyne Pharma (DYN) - Expected net earnings per share growth next year|EWTX - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Rapport Therapeutics, Inc.|ALMS: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Kempharm ZVRA|Expected earnings per share growth for next year CTNM|Expected net earnings per share growth next year Larimar Corp LRMR|Earnings growth forecast for next year CAPR|TRDA - Expected net earnings per share growth next year|Earnings growth forecast for next year PTHS (Channel Therapeutics Corp)|MediciNova Corp (MNOV) - Expected net earnings per share growth next year|Serina Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year BioXcel Therapeutics|PMN: Earnings growth forecast for next year|Expected earnings per share growth for next year Apimeds Pharmaceuticals, Inc.|Expected earnings per share growth for next year AEON|Expected net earnings per share growth next year bionomics.com.au BNOX|Earnings growth forecast for next year HUGE|RETA (Reata Pharma) - Expected earnings per share trend next year